A phase 2, randomized, double-blind, parallel-group study to assess the pharmacodynamics, safety/tolerability and efficacy of topical omiganan in patients with usual type vulvar intraepithelial neoplasia - Omiganan in patients with uVI

Cutanea Life Sciences0 个研究点目标入组 12 人开始时间: 待定最近更新: 2024年4月23日

适应症

试验速览

暂无简介。

•1. Women >= 18 years
•2. Biopsy proven uVIN, biopsies to have been taken within the last three months
•3. Written informed consent to participate in the trial
•4. At least one lesion that can be accurately measured (using RECIST criteria)
•o in at least one dimension with longest diameter >= 20mm
•o OR in two perpendicular dimensions that when multiplied together give a surface area of greater than 120mm2 (e.g. 15mm x 8mm or 12mm x 10mm)

•1. Has any concomitant disease or significant medical conditions that would, in the opinion of the Investigator, potentially compromise the safety or compliance of the patient or may preclude the patient's successful completion of the clinical trial.
•2. Clinically significant abnormalities, as judged by the Investigator, in laboratory test results (including hepatic and renal panels, complete blood count, chemistry panel and urinalysis) or ECG. In the case of uncertain or questionable results, tests performed during screening may be repeated before randomization to confirm eligibility or judged to be clinically irrelevant for healthy subjects.
•3. Indication of a current active infectious disease of the vulva, other than HPV
•4. Pregnant, breast feeding or trying to conceive
•5. Active treatment for uVIN within the previous eight weeks
•6. Patients receiving immunosuppressive therapy
•7. HIV positive or transplant patients
•8. Any condition that in the opinion of the investigator could interfere with the conduct of the study

发起方